326 related articles for article (PubMed ID: 33373595)
1. Interactions of α-synuclein oligomers with lipid membranes.
Musteikytė G; Jayaram AK; Xu CK; Vendruscolo M; Krainer G; Knowles TPJ
Biochim Biophys Acta Biomembr; 2021 Apr; 1863(4):183536. PubMed ID: 33373595
[TBL] [Abstract][Full Text] [Related]
2. Disruptive membrane interactions of alpha-synuclein aggregates.
Iyer A; Claessens MMAE
Biochim Biophys Acta Proteins Proteom; 2019 May; 1867(5):468-482. PubMed ID: 30315896
[TBL] [Abstract][Full Text] [Related]
3. A glimpse into the structural properties of α-synuclein oligomers.
Santos J; Pallarès I; Ventura S
Biofactors; 2024; 50(3):439-449. PubMed ID: 38063360
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles.
Meade RM; Fairlie DP; Mason JM
Mol Neurodegener; 2019 Jul; 14(1):29. PubMed ID: 31331359
[TBL] [Abstract][Full Text] [Related]
5. Polyunsaturated fatty acids induce alpha-synuclein-related pathogenic changes in neuronal cells.
Assayag K; Yakunin E; Loeb V; Selkoe DJ; Sharon R
Am J Pathol; 2007 Dec; 171(6):2000-11. PubMed ID: 18055555
[TBL] [Abstract][Full Text] [Related]
6. Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson's disease.
van Rooijen BD; Claessens MM; Subramaniam V
Curr Protein Pept Sci; 2010 Aug; 11(5):334-42. PubMed ID: 20423294
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic aspects of Parkinson's disease: alpha-synuclein and the biomembrane.
Beyer K
Cell Biochem Biophys; 2007; 47(2):285-99. PubMed ID: 17652776
[TBL] [Abstract][Full Text] [Related]
8. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain.
Roberts RF; Wade-Martins R; Alegre-Abarrategui J
Brain; 2015 Jun; 138(Pt 6):1642-57. PubMed ID: 25732184
[TBL] [Abstract][Full Text] [Related]
9. Loss of native α-synuclein multimerization by strategically mutating its amphipathic helix causes abnormal vesicle interactions in neuronal cells.
Dettmer U; Ramalingam N; von Saucken VE; Kim TE; Newman AJ; Terry-Kantor E; Nuber S; Ericsson M; Fanning S; Bartels T; Lindquist S; Levy OA; Selkoe D
Hum Mol Genet; 2017 Sep; 26(18):3466-3481. PubMed ID: 28911198
[TBL] [Abstract][Full Text] [Related]
10. Interaction of α-synuclein with biomembranes in Parkinson's disease--role of cardiolipin.
Ghio S; Kamp F; Cauchi R; Giese A; Vassallo N
Prog Lipid Res; 2016 Jan; 61():73-82. PubMed ID: 26703192
[TBL] [Abstract][Full Text] [Related]
11. From a Highly Disordered to a Metastable State: Uncovering Insights of α-Synuclein.
Cote Y; Delarue P; Scheraga HA; Senet P; Maisuradze GG
ACS Chem Neurosci; 2018 May; 9(5):1051-1065. PubMed ID: 29451381
[TBL] [Abstract][Full Text] [Related]
12. Cardiolipin Promotes Pore-Forming Activity of Alpha-Synuclein Oligomers in Mitochondrial Membranes.
Ghio S; Camilleri A; Caruana M; Ruf VC; Schmidt F; Leonov A; Ryazanov S; Griesinger C; Cauchi RJ; Kamp F; Giese A; Vassallo N
ACS Chem Neurosci; 2019 Aug; 10(8):3815-3829. PubMed ID: 31356747
[TBL] [Abstract][Full Text] [Related]
13. Membrane binding of oligomeric alpha-synuclein depends on bilayer charge and packing.
van Rooijen BD; Claessens MM; Subramaniam V
FEBS Lett; 2008 Nov; 582(27):3788-92. PubMed ID: 18930058
[TBL] [Abstract][Full Text] [Related]
14. β-Synuclein: An Enigmatic Protein with Diverse Functionality.
Hayashi J; Carver JA
Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053291
[TBL] [Abstract][Full Text] [Related]
15. Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy.
Sultana Z; Paleologou KE; Al-Mansoori KM; Ardah MT; Singh N; Usmani S; Jiao H; Martin FL; Bharath MM; Vali S; El-Agnaf OM
Neuroscience; 2011 Dec; 199():303-17. PubMed ID: 22056602
[TBL] [Abstract][Full Text] [Related]
16. [Alpha-Synuclein in blood and cerebrospinal fluid of patients with alpha-synucleinopathy].
Ono K; Yamada M
Rinsho Byori; 2014 Mar; 62(3):241-5. PubMed ID: 24800499
[TBL] [Abstract][Full Text] [Related]
17. Α-synuclein misfolding and Parkinson's disease.
Breydo L; Wu JW; Uversky VN
Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of α-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson's disease.
Matsui H; Ito S; Matsui H; Ito J; Gabdulkhaev R; Hirose M; Yamanaka T; Koyama A; Kato T; Tanaka M; Uemura N; Matsui N; Hirokawa S; Yoshihama M; Shimozawa A; Kubo SI; Iwasaki K; Hasegawa M; Takahashi R; Hirai K; Kakita A; Onodera O
Proc Natl Acad Sci U S A; 2023 Jun; 120(23):e2214652120. PubMed ID: 37252975
[TBL] [Abstract][Full Text] [Related]
19. Nicotine slows down oligomerisation of α-synuclein and ameliorates cytotoxicity in a yeast model of Parkinson's disease.
Kardani J; Sethi R; Roy I
Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1454-1463. PubMed ID: 28167231
[TBL] [Abstract][Full Text] [Related]
20. Targeting alpha-synuclein for the treatment of Parkinson's disease.
Rohn TT
CNS Neurol Disord Drug Targets; 2012 Mar; 11(2):174-9. PubMed ID: 22483285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
